US Food and Drug Administration review for use as a psoriasis treatment. In this multicenter study, patients received subcutaneous injections of either a single dose of 45 mg or 90 mg ustekinumab or four weekly injections of the same doses or placebo. In this multicenter Phase 2 trial, 146 patients with active plaque psoriasis and inadequate responses to conventional drug treatments were enrolled. It is under investigation in the treatment of psoriatic arthritis and Crohn disease. Certain cytokines cause skin cells to grow rapidly, producing plaques of psoriasis. Ustekinumab is a monoclonal antibody that targets the p40 subunit of the cytokines IL-12 and IL-23, preventing them from binding and activating T-lymphocytes. The second dose is given 4 weeks after the first injection, and further doses are delivered every 12 weeks. Ustekinumab injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in people whose psoriasis is too severe to be treated by topical medications alone. Ustekinumab injection is in a class of medications called monoclonal antibodies.
Ustekinumab is the most recent monoclonal antibody (biologic) approved in the U. Because these drugs are also used to treat psoriasis, this rebound effect is of particular concern. Body-wide (systemic) medications, which are pills or injections that affect the whole body, not just the skin. Psoriasis Online Medical Reference – from diagnosis through treatment. Plaque-type psoriasis, or psoriasis vulgaris, is the most common form, occurring in about 80 of all psoriasis patients. Ustekinumab utilizes monoclonal antibodies directed against the p40 subunit of cytokines IL-12 and IL-23, which have been recently described as significant mediators of psoriasis. Includes indications, proper use, special instructions, precautions, and possible side effects. Diagnosed with psoriatic arthritis? Treating certain patients with moderate to severe plaque psoriasis. Ustekinumab is a monoclonal antibody. Ustekinumab is usually given as an injection at your doctor’s office, hospital, or clinic.
Plaque psoriasis (Ps) when all of the following are met: Individual is 18 years of age or older with chronic moderate to severe plaque Ps with either of the following: Plaque Ps involving greater than 5 body surface area (BSA); or. Use of ustekinumab in combination with other immunosuppressive therapy or phototherapy; or. Ustekinumab is a fully human monoclonal antibody that selectively binds with high specificity and affinity to the cytokines IL-12 and IL-23, thereby suppressing IL-12 and IL-23-mediated inflammation associated with psoriasis. Adverse events (AE) were generally similar across treatment and control groups, including infections, injection-site reactions, psychological disorders, and development of anti-ustekinumab antibodies. For patients with co-existent moderate to severe plaque psoriasis weighing more than 220 lbs. (100 kg) the recommended dose is 90 mg subcutaneous injection at weeks 0 and 4, and then every 12 weeks, thereafter. Ustekinumab is a laboratory-produced antibody that treats psoriasis by blocking the action of two proteins (interleukins) that contribute to the overactive skin inflammation. It is currently not for home use or self-injection. It is an interleukin-12/23 human monoclonal antibody. Scales, Plaques & Eruptions.
Ustekinumab, a human monoclonal antibody against interleukins 12 and 23, has shown therapeutic potential for psoriasis. Most patients had used conventional systemic or biological agents to treat their psoriasis. (IL-23) monoclonal antibody (MAb), is a novel investigational therapy for plaque psoriasis developed by Centocor (a subsidiary of J&J). The approval granted use of ustekinumab in 27 countries across Europe for treating moderate to severe plaque psoriasis in adults. Plaque psoriasis is a common skin disorder, in which patients develop characteristic raised erythematous skin lesions with silvery-white scales. The assessment found that the general efficacy of adalimumab, alefacept, etanercept, infliximab, and ustekinumab for the treatment of moderate to severe plaque psoriasis was supported by multiple good to fair randomized controlled trials. Efalizumab, a once-weekly subcutaneously injected drug, is a humanized anti-CD11a monoclonal antibody.